This page shows the latest MeiraGTx news and features for those working in and with pharma, biotech and healthcare.
Licenses two inherited retinal disorder candidates. Johnson &Johnson has made its biggest move into gene therapy, signing a $100m deal with UK-headquartered biotech MeiraGTx for rights to two genetic eye ... MeiraGTx is also working on gene therapies for
MeiraGTx is developing therapies for diseases of the eye, salivary glands and central nervous system. ... Funds raised from the IPO will enable MeiraGTx to progress its product candidates to treat inherited rare eye diseases, xerostomia (‘dry mouth’)
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...